Biotechnology
Technology
Health

BioLineRx

$0.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BioLineRx and other stocks, options, ETFs, and crypto commission-free!

About

BioLineRx Ltd. American Depositary Shares, also called BioLineRx, is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Read More Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Employees
51
Headquarters
Modi'in, Tel Aviv
Founded
2003
Market Cap
47.56M
Price-Earnings Ratio
Dividend Yield
Average Volume
791.79K
High Today
$0.4411
Low Today
$0.435
Open Price
$0.441
Volume
249.46K
52 Week High
$1.84
52 Week Low
$0.38

Collections

Biotechnology
Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Asia (Non-China)
Asia

News

PR NewswireMar 14

BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference

TEL AVIV, Israel, March 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin, will present a company update at the 29th Annual Oppenheimer Healthcare Conference on Tuesday, March 19, 2019 at 3:20 p.m. (EDT). The conference will be held at the Westin Grand Central Hotel in New York, NY. A live webcast of the presentation will be available on BioLineRx's website. A r...

197
MarketBeatMar 2

Stock Price, News, & Analysis for BIOLINERX LTD/S

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Nov...

33

Earnings

-$0.09
-$0.08
-$0.06
-$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.09 per share
Actual
Expected Mar 26, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.